OR WAIT null SECS
July 25, 2024
Article
The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.
July 23, 2024
Spigler provides insight into the development of new patient-focused guidelines for managing hyperkalemia in CKD and the importance of providing patients with such resources.
July 13, 2024
Video
Neuen explains the cardiovascular and kidney benefits of combining SGLT2 inhibitors and GLP-1 receptor agonists in diabetes and the future of combination therapy.
July 12, 2024
The patient-focused guidelines were developed by the American Kidney Fund and AstraZeneca to help people with CKD manage high potassium.
July 09, 2024
Findings from a meta-analysis examining 12 trials including more than 70,000 patients with diabetes support combining SGLT2 inhibitors and GLP-1 RAs.
July 01, 2024
This June 2024 month in review spotlights HCPLive’s coverage of the latest renal news and research in IgA nephropathy, differences in care, and novel associations in nephrology.
June 25, 2024
Data on outcomes stratified according to baseline use of SGLT2 inhibitors from the FLOW trial were presented at ADA 2024.
June 24, 2024
Findings highlight the potential utility of low-dose SGLT2 inhibitors for optimizing diabetes control and managing renal complications in pediatric patients with type 1 diabetes.
June 12, 2024
Results showed eGFR was linked to having ≥ 20 adult teeth in postmenopausal women, highlighting increased tooth loss among participants with CKD versus those without.
June 07, 2024
Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.